Although the CAMELIA trial addresses the management of HIV/TB coinfected persons with CD4 counts <200/mm3, recommendations regarding the optimal timing of HAART for coinfected individuals with CD4 counts >200/mm3 may not be derived from this trial or from the recently concluded ACTG A5221 study. The gene discussed is CD4; the disease is tuberculosis.